Animal testing affects far more groups than most people realize. The obvious answer is the animals themselves, but the ripple effects extend to laboratory workers, patients waiting for new medicines, consumers buying everyday products, and even surrounding communities exposed to biomedical waste. Here’s how each group is impacted.
The Animals
Millions of animals are used in research worldwide each year. Mice and rats make up the vast majority, but the list also includes rabbits, dogs, primates, fish, and birds. These animals are used for everything from basic biological research to safety testing for new drugs and chemicals. Many undergo procedures that cause pain or distress, and most are euthanized at the end of a study.
Primates have historically carried an especially heavy burden. Millions were used to produce polio vaccines in the 1950s alone. Today, primate use has decreased in many countries, but they remain part of research programs for neurological and infectious disease studies where their biology most closely mirrors human responses.
Laboratory Workers
The psychological toll on people who work with research animals is significant and largely invisible to the public. A cross-sectional study published in the Journal of the American Association for Laboratory Animal Science found that roughly two-thirds of laboratory animal professionals reported experiencing compassion fatigue at some point in their careers. The numbers were consistent whether workers were employed at academic institutions (66%) or contract research organizations (69%).
The most commonly reported feelings were exhaustion (83%), apathy (76%), sadness (71%), depression (64%), anxiety (64%), and guilt (60%). More than half of those affected said they were always or often stressed at work, and 61% felt that compassion fatigue negatively affected their ability to do their job. Broader research on animal care professionals links these symptoms to loss of empathy, isolation, substance abuse, trouble sleeping, and physical health problems. Common coping mechanisms include talking through feelings with colleagues, adjusting emotional attachment to the animals, and finding personal meaning in why certain procedures are necessary.
Patients Waiting for New Treatments
Animal testing has contributed to some of the most important medical advances in history. Louis Pasteur developed vaccines for anthrax, cholera, and rabies through animal experiments in the 19th century, laying the foundation for modern immunology. The first diphtheria antitoxin was developed from horse serum. Paul Ehrlich’s animal research led to an effective treatment for syphilis. These breakthroughs, and many that followed, relied directly on animal models.
But the system is far from efficient. Only about 12% of drugs that pass preclinical animal testing make it into human clinical trials. Of those, just 60% successfully complete Phase I safety trials. Overall, roughly 89% of new drugs fail during human trials, and about half of those failures are due to toxic effects that animal testing didn’t predict. That gap matters enormously for patients. It means promising treatments get delayed or abandoned, while other compounds that look safe in animals turn out to be harmful in people. The disconnect between animal biology and human biology is a core limitation of the current system.
Consumers and the Cosmetics Industry
For decades, cosmetics and personal care products were routinely tested on animals before reaching store shelves. That’s changing rapidly. The UK banned cosmetic animal testing in 1998, and the European Union phased in a near-total ban by 2013, including on imported ingredients tested on animals. Since then, more than a dozen jurisdictions have followed: India (2014), Israel (2013), New Zealand (2015), Taiwan (2019), Colombia (2020), Guatemala (2017), Canada (2023), and the four countries of the European Free Trade Association (Norway, Liechtenstein, Switzerland, and Iceland).
These bans affect consumers in two ways. In countries with bans, shoppers can buy cosmetics knowing that no new animal testing was involved in their development. In countries without bans, particularly the United States and China, consumers who want to avoid animal-tested products still need to check for voluntary certifications and brand policies. China has historically required animal testing for imported cosmetics, though it has loosened some of those rules in recent years, creating a complicated landscape for global beauty brands trying to go cruelty-free.
How Regulations Are Shifting
In the United States, the FDA has announced plans to phase out animal testing requirements for certain drug categories, starting with monoclonal antibodies. The agency will encourage companies to submit safety data from non-animal methods, including AI-based toxicity models, cell lines, and lab-grown organ models (sometimes called organoids). Companies that submit strong non-animal safety data may receive streamlined review, which creates a financial incentive to invest in these newer testing methods.
Implementation is already underway for new drug applications, and the FDA plans to launch a pilot program allowing select developers to use a primarily non-animal testing strategy. This shift doesn’t eliminate animal testing overnight, but it marks the first time the agency has formally moved toward making it optional rather than mandatory for specific drug types. For patients, this could eventually mean faster development timelines. For animals and lab workers, it means fewer procedures over time.
Environmental and Community Effects
Animal research facilities generate biomedical waste that poses risks to surrounding communities and ecosystems if not handled properly. This waste includes animal remains, contaminated bedding, sharps, and chemical residues from laboratory reagents, solvents like formalin and methanol, and disinfectants. While 75% to 90% of healthcare waste overall is comparable to ordinary trash, the remaining 10% to 25% is classified as hazardous.
Disposal methods carry their own risks. Landfills can contaminate drinking water if they aren’t properly constructed. Incineration, the most common disposal method, can release dioxins and furans (known human carcinogens) when waste containing chlorine is burned. Burning materials with high metal content can spread lead, mercury, and cadmium into the surrounding air. Only modern incinerators operating at very high temperatures with specialized gas-cleaning equipment meet international emission standards. In lower-income countries, where waste infrastructure is less developed, these risks are amplified. Pharmaceutical compounds and antibiotics from research waste can also enter water systems, contributing to broader concerns about drug-resistant bacteria in the environment.